CLL is diagnosed in roughly 15,700 persons annually in the United States.
https://www.lls.org/sites/default/files/file_assets/facts.pdf
GILD has announced that the success rate of their drug Zydelig has been so successful that the study data resulted in an unbinding of the placebo control group, which is exceedingly rare.
http://finance.yahoo.com/news/gilead-zydelig-combined-bendamustine-rituximab-140000081.html
Estimated annual sales of $2.4 billion by 2020 may result from wider adoption and a faster rollout of this product, based upon the results.
Leave a Reply
You must be logged in to post a comment.